糖尿病合并高血压加重血管病变的研究进展

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (7): 990-994.

糖尿病合并高血压加重血管病变的研究进展

刘宁, 张伟华^*

哈尔滨医科大学基础医学院病理生理学教研室, 黑龙江哈尔滨 150086

收稿日期:2020-03-10 修回日期:2020-04-23 出版日期:2020-07-05 发布日期:2020-06-29
通讯作者: ^*Zhangwh116@126.com
基金资助:
国家自然科学基金(81970317,81670344);哈尔滨医科大学校创新基金(2018)

Progress of research on diabetes with hypertension aggravating vascular disease

LIU Ning, ZHANG Wei-hua^*

Department of Pathophysiology, School of Basic Medicine, Harbin Medical University, Harbin 150086, China

Received:2020-03-10 Revised:2020-04-23 Online:2020-07-05 Published:2020-06-29
Contact: ^*Zhangwh116@126.com

摘要/Abstract

摘要： 糖尿病发病和死亡的主要原因是心血管疾病的发生,而高血压加重心血管疾病。糖尿病和高血压具有相似的危险因素,并且相关心血管并发症也有大量重叠。因此,糖尿病和高血压密切相关。控制合并症,特别是高血压,对于减缓糖尿病的血管病变尤为重要。

关键词: 糖尿病, 高血压, 合并症, 心血管并发症

Abstract: The major cause of morbidity and mortality of diabetes is cardiovascular disease, which is exacerbated by hypertension. Diabetes and hypertension are closely interlinked because of similar risk factors, and there is also substantial overlap in the cardiovascular complications of diabetes and hypertension. Controlling comorbidities, especially hypertension, is important in reducing the vascular complications of diabetes.

Key words: diabetes, hypertension, comorbidities, cardiovascular complications

中图分类号:

刘宁, 张伟华. 糖尿病合并高血压加重血管病变的研究进展[J]. 基础医学与临床, 2020, 40(7): 990-994.

LIU Ning, ZHANG Wei-hua. Progress of research on diabetes with hypertension aggravating vascular disease[J]. Basic & Clinical Medicine, 2020, 40(7): 990-994.

参考文献

[1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition[J]. Diabetes Res Clin Pract, 2019, 157: 107843. doi: 10.1016/j.diabres.2019.107843.
[2] Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries[J]. Circulation, 2016, 134: 441-450.
[3] Horr S, Nissen S. Managing hypertension in type 2 diabetes mellitus[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30: 445-454.
[4] Choby B. Diabetes update: prevention and management of diabetes complications[J]. FP Essent, 2017, 456: 36-40.
[5] Fishman SL, Sonmez H, Basman C, et al. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review[J]. Mol Med, 2018, 24: 59-90.
[6] Luc K, Schramm-Luc A, Guzik TJ, et al. Oxidative stress and inflammatory markers in prediabetes and diabetes[J]. J Physiol Pharmacol, 2019, 70. doi: 10.26402/jpp.2019.6.01.
[7] Zhang Y, Sun X, Icli B, et al. Emerging roles for microRNAs in diabetic microvascular disease: Novel targets for therapy[J]. Endocr Rev, 2017, 38: 145-168.
[8] Antoniades C. ‘Dysfunctional' adipose tissue in cardiovascular disease: A reprogrammable target or an innocent bystander?[J]. Cardiovasc Res, 2017, 113: 997-998.
[9] Camastra S, Vitali A, Anselmino M, et al. Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery[J]. Sci Rep, 2017, 7: 9007-9025.
[10] Jung UJ. Choi MS. Obesity and its metabolic complica-tions: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2014, 15: 6184-6223.
[11] Shi X, Wang S, Luan H, et al. Clinopodium chinense attenuates palmitic acid-induced vascular endothelial inflammation and insulin resistance through TLR4-mediated NF-kappa B and MAPK pathways[J]. Am J Chin Med, 2019, 47: 97-117.
[12] Guzik TJ, Touyz RM. Oxidative stress, inflammation, and vascular aging in hypertension[J]. Hypertension, 2017, 70: 660-667.
[13] Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both?[J]. Curr Diab Rep, 2014, 14: 453-471.
[14] Nigro C, Leone A, Raciti GA, et al. Methylglyoxal-glyoxalase 1 balance: the root of vascular damage[J]. Int J Mol Sci, 2017, 18: E188.doi:10.3390/ijms18010188.
[15] Manigrasso MB, Juranek J, Ramasamy R, et al. Unlock-ing the biology of RAGE in diabetic microvascular complications[J]. Trends Endocrinol Metab, 2014, 25: 15-22.
[16] Koulis C, Watson AM, Gray SP, et al. Linking RAGE and Nox in diabetic micro- and macrovascular complications[J]. Diabetes Metab, 2015, 41: 272-281.
[17] Correction to: 2016 ATVB plenary lecture: receptor for advanced glycation endproducts and implications for the pathogenesis and treatment of cardiometabolic disorders: Spotlight on the macrophage[J]. Arterioscler Thromb Vasc Biol, 2017, 37: e66.doi:10.1161/ATV.0000000000000057.
[18] Meza CA, La Favor JD, Kim DH, et al. Endothelial dysfunction: Is there a hyperglycemia-induced imbalance of NOX and NOS?[J]. Int J Mol Sci, 2019, 20: 3775.doi:10.3390/ijms20153775.
[19] Petrie JR, Guzik TJ, and Touyz RM. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms[J]. Can J Cardiol, 2018, 34: 575-584.
[20] Guzik TJ, Cosentino F. Epigenetics and immunometabolism in diabetes and aging[J]. Antioxid Redox Signal, 2018, 29: 257-274.
[21] Naidoo V, Naidoo M, Ghai M. Cell- and tissue-specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus[J]. Scand J Immunol, 2018, 88: e12723. doi: 10.1111/sji.12723.
[22] Hyun MH, Lee Y, Choi BG, et al. Roles of achieved levels of low-density lipoprotein cholesterol and high-sensitivity c-reactive protein on cardiovascular outcome in statin therapy[J]. Cardiovasc Ther, 2019, 2019: 1-11.
[23] Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy[J]. Cardiovasc Res, 2017, 113: 389-398.
[24] Banerjee J, Nema V, Dhas Y, et al. Role of microRNAs in type 2 diabetes and associated vascular complications[J]. Biochimie, 2017, 139: 9-19.
[25] Sharma A, Rizky L, Stefanovic N, et al. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction[J]. Cardiovasc Diabetol, 2017, 16: 33-56.